Table 3.
Response evaluation.
| No | Registration data | Refractory Pheochromocytoma/Paraganglioma | Response to 131I-mIBG therapy | |||
|---|---|---|---|---|---|---|
| BOR based on RECIST | CE based on 123I-mIBG scintigraphy | |||||
| 1st course | 2nd course | 3rd course | ||||
| 1 | 2.29.2016 | Pheochromocytoma | SD | CR | — | — |
| 2 | 3.4.2016 | Pheochromocytoma | SD | PR | PR | PR |
| 3 | 3.17.2016 | Paraganglioma | SD | PR | SD | PR |
| 4 | 5.11.2016 | Pheochromocytoma | NE | non-CR/non-PD | PD | — |
| 5 | 5.18.2016 | Paraganglioma | SD | PR | — | — |
| 6 | 6.9.2016 | Paraganglioma | PD | PD | — | — |
| 7 | 7.13.2016 | Pheochromocytoma | CR | CR | CR | — |
| 8 | 7.29.2016 | Paraganglioma | SD | SD | SD | — |
| 9 | 7.29.2016 | Pheochromocytoma | SD | SD | SD | PR |
| 10 | 10.6.2016 | Pheochromocytoma | PD | PD | — | — |
| 11 | 10.13.2016 | Paraganglioma | PD | PD | — | — |
| 12 | 10.24.2016 | Paraganglioma | SD | PD | — | — |
| 13 | 11.24.2016 | Pheochromocytoma | CR | PR | PR | — |
| 14 | 1.13.2017 | Pheochromocytoma | SD | SD | SD | — |
| 15 | 2.6.2017 | Pheochromocytoma | SD | SD | — | — |
| 16 | 2.9.2017 | Pheochromocytoma | SD | PR | — | — |
| 17 | 2.10.2017 | Pheochromocytoma | SD | SD | — | — |
| 18 | 3.1.2017 | Pheochromocytoma | NE | SD | — | — |
| 19 | 4.21.2017 | Pheochromocytoma | SD | SD | — | — |
| 20 | 7.14.2017 | Paraganglioma | SD | SD | — | — |
mIBG: meta-iodobenzylguanidine; BOR: best overall response; CE: comprehensive evaluation; RECIST: Response Evaluation Criteria in Solid Tumours; CR: complete response; PR: partial response; NE: not evaluated; PD: progression disease; SD: stable disease.